AstraZeneca to create separate division for vaccines, antibody therapies
The Anglo-Swedish company was exploring options for its vaccine business and expected to have greater clarity on the matter by the end of 2021
Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
AstraZeneca is creating a separate division for vaccines and antibody therapies to be led by senior executive Iskra Reić, the drugmaker said on Tuesday, as it builds focus on its Covid-19 shot and development of coronavirus treatments.
Reuters in July reported that the Anglo-Swedish company was exploring options for its vaccine business and expected to have greater clarity on the matter by the end of 2021.
Keep updated, follow The Business Standard's Google news channel
